Biofabri

Focus: Biofabri is a Spanish biotechnology company founded in 2008 specializing in vaccines and immunotherapy for infectious diseases, particularly tuberculosis. The company operates at a modest scale with a focused pipeline centered on novel vaccine development.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biofabri

AI assessmentNot Hiring

No open roles listed right now. Follow Biofabri to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Quantiferon Gold Plus Test

Tuberculosis

N/A

Clinical Trials (1)

NCT03767946Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal

N/A

Help build intelligence for Biofabri

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead development of MTBVAC, a Phase 3 TB vaccine addressing a major global health need with significant market potential
Work in an emerging therapeutic area (vaccines and immunotherapy) with multiple pipeline programs spanning TB, HIV, and bladder cancer
Contribute to a company with 15+ years of expertise in infectious disease and immunological approaches with diversified indications

Watch Out For

Currently zero open job positions signals potential hiring freeze, limited growth trajectory, or operational challenges
Reliance on a single lead asset (MTBVAC) across multiple indications creates concentration risk if clinical outcomes disappoint
Limited public financial data and absence of revenue information makes career stability and compensation competitiveness difficult to assess

Generated by Claude from Biofabri's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MTBVAC live vaccine

Tuberculosis

Phase 1

Clinical Trials (1)

NCT02013245Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

Phase 1

MTBVAC

Tuberculosis

Phase 1/2

Clinical Trials (1)

NCT02729571Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

Phase 1/2